The fluorescent images show that CPMV and CCMV do not home to lungs and are mainly cleared by other organs such as the liver (75%), spleen (14–18%), and kidneys (6–10%) (Figure 3b,c and Figure S5b,c, Supporting Information, respectively), as previously reported.[35] Likewise, the S100A9‐targetd CPMV and CCMV nanoparticles accumulated in the liver and spleen, but there was also significant accumulation within the lungs regardless of tumor inoculation. The gene discussed is S100A9; the disease is neoplasm.